Thus, the low levels of serum IL-6, CXCL8 and VEGF observed in Nivolumab-responding patients after two months of therapy might reflect, in these subjects, the effective capability of the treatment to counteract chronic inflammation-driven progression of the tumor, while the high concentrations of CCL2 might indicate a better infiltration of immune cells within neoplastic lesions, both resulting in longer OS and PFS. The gene discussed is CCL2; the disease is neoplasm.